You are here

Article Text

Article menu
Download PDFPDF
Commentary
To be or not 2b? To see or not 2c? Alas, the clock is ticking on TICI

https://doi.org/10.1136/neurintsurg-2017-013521

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors All authors contributed to the conception, drafting, revisions and approval of this commentary. DFK is the guarantor of this work.

    • Competing interests DFK: Consulting for Medtronic (all funds to the institution), ownership stake in Marblehead Medical, and has received research support from Medtronic, MicroVention, NeuroSigma, Shape Memory Therapeutics, IndumedX, Sequent Medical, Neurogami, and NeuroSave. AAR: Received funding from DJO Global. MJG: Has been consultant on a fee-per-hour basis for Codman Neurovascular, InNeuroCo, Medtronic Neurovascular, and Stryker Neurovascular; holds stock in InNeuroCo; and has received research support from the National Institutes of Health (NIH), Anaconda, Codman Neurovascular, Gentuity, InNeuroCo, Microvention, Medtronic Neurovascular, MIVI Neurosciences, Neuravi, Philips Healthcare, InNeuroCo, Rapid Medical, R92M, Stryker Neurovascular, The Stroke Project, and the Wyss Institute.

    • Provenance and peer review Not commissioned; externally peer reviewed.